An interventional study of Training in Chronic Obstructive Pulmonary Diseases, COPD and Symptom Exacerbation, sponsored by KU Leuven. Recruiting at 12 sites in Belgium. Open to participants aged 35 Years and older. Per ClinicalTrials.gov, last updated 2026-05-28.
Sponsored by KU Leuven · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Pulmonary Disease, Chronic Obstructive by KU Leuven — 2 open to participants now, 2 under way, none of them phase 3. Pulmonary Disease, Chronic Obstructive · KU Leuven.
Among the 27 studies in Pulmonary Disease, Chronic Obstructive by KU Leuven, this one is the 2nd largest by planned enrollment of the 19 interventional ones that give a count, is the only one that started in 2026, is one of 16 with no phase, and was the 27th registered.
5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →2 of the 27 studies in Pulmonary Disease, Chronic Obstructive by KU Leuven are open now, in 1 country. Recruiting first, the newest first:
KU Leuven · Sites in Belgium
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.
This study: 35 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 358 is above the median of 62 across 3,847 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 70 across the 19 interventional studies, 138 across the 8 observational. Of the 15 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
KU Leuven is the lead sponsor of 373 studies on the registry; 65 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 27 studies in Pulmonary Disease, Chronic Obstructive by KU Leuven, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to test whether home-based inspiratory muscle training can reduce hospital readmissions and death in patients recovering from a severe acute exacerbation of chronic obstructive pulmonary disease (AECOPD).
The main questions this study aims to answer are:
Does adding home-based inspiratory muscle training to usual care lower the risk of all-cause hospital readmission or death within 180 days after discharge? Does inspiratory muscle training improve respiratory muscle strength, symptoms of dyspnea, quality of life, and functional capacity compared to usual care?
Researchers will compare patients randomized to:
Intervention group: Home-based inspiratory muscle training plus usual care Control group: Usual care only
to see if inspiratory muscle training leads to fewer readmissions and deaths, and better patient-reported and physiological outcomes.
Participants will:
Be hospitalized for ≥3 days due to AECOPD, age ≥35 years, able to consent, and own a compatible smartphone.
In the intervention group, receives usual care and additionally inspiratory muscle training:
Inspiratory muscle training twice daily for 90 days, then once daily up to day 180, with remote telemonitoring via a smartphone app and online supervised sessions.
The control group will continue with usual care (pharmacological treatment, smoking cessation advice, vaccinations, and referral to pulmonary rehabilitation if available).
Follow-up assessments will include hospital readmissions, survival, and quality of life questionnaires up to 12 months after discharge.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Training
Patients will receive usual care, including optimal pharmacological therapy per international guidelines, advise on smoking cessation, vaccination, and physical activity participation and advised to attend physiotherapy or a respiratory rehabilitation program based on accessibility and patient preference.
home-based inspiratory muscle training (IMT) will be delivered using a portable IMT device connected via Bluetooth to a smartphone application that provides real-time feedback, adherence monitoring, and telemonitoring by the study team. Patients will train for 365 days following hospital discharge due to an acute exacerbation of COPD: * Intensive phase (Day 0-90): 2 daily sessions, each consisting of 30 breaths against an inspiratory load set by thetelemonitor, with regular online supervised IMT sessions, 7 sessions in total * Maintenance phase (Day 91-180): One daily session of 30 breaths, with sporadic online supervised IMT sessions, 2 sessions in total. * Follow-up phase (Day 181-365): Participants may continue IMT unsupervised. Supervision includes both in-person sessions at hospital visits and online sessions with telemonitors.
Composite outcome (all-cause hospital readmission or mortality)
Time frame: within 180 days after hospital discharge
Composite outcome (all-cause hospital readmission or mortality)
Occurrence
Time frame: within 90 days after hospital discharge
Time-to-composite outcome (all-cause hospital readmission or mortality)
Time-to-event
Time frame: within 180 days after hospital discharge
Hospital re-admission
1. Occurrence 2. Reason
Time frame: Day 28, 90 and 180 after hospital discharge
All-cause mortality
1. Occurrence 2. Reason
Time frame: Day 28, 90 and 180 after hospital discharge
Primary care and specialty consultationsc
Number of days post-discharge
Time frame: Day 90 and 180 after hospital discharge
Re-exacerbation
1. Occurrence 2. Number of occurrences/patient post-discharge
Time frame: Day 90 and 180 after hospital discharge
Change in Forced Expiratory Volume in 1 Second (FEV₁), liters
\- Mean change in FEV₁ (liters) from baseline, measured by spirometry, according to ATS/ERS guidelines.
Time frame: Day 90 and 180 after hospital discharge
Change in Forced Expiratory Volume in 1 Second (FEV₁), %pred
\- Mean change in FEV₁ (% predicted) from baseline, measured by spirometry.
Time frame: Day 90 and 180 after hospital discharge
Change in Forced Vital Capacity (FVC), liters
\- Mean change in FVC (liters) from baseline, measured by spirometry.
Time frame: Day 90 and Day 180 after hospital discharge
Change in Forced Vital Capacity (FVC), %predicted
\- Mean change in FVC (% predicted) from baseline, measured by spirometry.
Time frame: Day 90 and Day 180 after hospital discharge
Change in FEV₁/FVC Ratio (%)
Mean change in the ratio of FEV₁ to FVC (percentage) from baseline, measured by spirometry.
Time frame: Day 90 and Day 180 after hospital discharge
Change in Functional Residual Capacity (FRC), liters
\- Mean change in FRC (liters) from baseline, measured by body plethysmography.
Time frame: Day 180 after hospital discharge
Change in Functional Residual Capacity (FRC), %predicted
\- Mean change in FRC (% predicted) from baseline, measured by body plethysmography.
Time frame: Day 180 after hospital discharge
Change in Residual Volume (RV), liters
\- Mean change in RV (liters) from baseline, measured by body plethysmography.
Time frame: Day 180 after hospital discharge
Change in Residual Volume (RV), % predicted
\- Mean change in RV (% predicted) from baseline, measured by body plethysmography.
Time frame: Day 180 after hospital discharge
Change in Total Lung Capacity (TLC), liters
\- Mean change in TLC (liters) from baseline, measured by body plethysmography.
Time frame: Day 180 after hospital discharge
Change in Total Lung Capacity (TLC), %predicted
\- Mean change in TLC (% predicted) from baseline, measured by body plethysmography.
Time frame: Day 180 after hospital discharge
Maximal inspiratory pressure (PImax)
Change from baseline
Time frame: Day 90 and 180 after hospital discharge
Baseline/Transition Dyspnea Index (BDI/TDI)
Change from baseline
Time frame: Day 28, 90, 180 after hospital discharge
EQ-5D-5L questionnaire
Change from baseline
Time frame: Day 28, 90, 180 after hospital discharge
COPD Assessment test (CAT)
Change from baseline
Time frame: Day 28, 90, 180 after hospital discharge
Adverse events
1. Occurrence 2. Number of occurrences/patient post-discharge
Time frame: Day 90, 180 after hospital discharge
Serious adverse events
1. Occurrence 2. Number of occurrences/patient post-discharge
Time frame: Day 90 and 180 after hospital discharge
Intensive care unit admission
Number of days post-discharge
Time frame: Day 90, 180, 365 after hospital discharge
Lung function: Diffusion capacity
Mean of 2 acceptable assessments
Time frame: Day 180 after hospital discharge
1 minute sit-to-stand test, Repetitions from Baseline
Mean change in the number of repetitions completed in the 1-minute sit-to-stand test compared with baseline.
Time frame: Day 180 after hospital discharge
Number of Participants Achieving the Minimal Important Difference (MID) in the 1-Minute Sit-to-Stand Test
Number of participants who improved their 1-minute sit-to-stand repetitions by more than the minimal important difference (MID)
Time frame: Day 180 after hospital discharge
Hospital Anxiety & Depression Scale (HADS)
Change from baseline
Time frame: Day 90 and 180 after hospital discharge
EQ-5D-5L
Change from baseline
Time frame: Day 365 after hospital discharge
COPD Assessment test (CAT)
Change from baseline
Time frame: Day 365 after hospital discharge
Baseline/Transition Dyspnea Index (BDI/TDI)
Change from baseline
Time frame: Day 365 after hospital discharge
Hospital re-admission
Time to event
Time frame: Day 365 after hospital discharge
All-cause mortality
1. Time to event 2. Reason
Time frame: Day 365 after hospital discharge
Rate of AECOPD treated with systemic corticosteroids
1. Occurrence 2. Time to event
Time frame: Day 90, 180, 365 after hospital discharge
Rate of AECOPD treated with antibiotics
1. Occurrence 2. Time to event
Time frame: Day 90, 180, 365 after hospital discharge
Plan to share: No — At this time, there are no plans to share individual participant data (IPD). De-identified participant-level data will not be made publicly available. However, summary results of the trial will be published in peer-reviewed journals and presented at scientific meetings. Researchers interested in secondary analyses may contact the sponsor (UZ Leuven) to discuss possibilities for collaborative projects, subject to approval by the Trial Steering Committee and compliance with applicable regulations and GDPR.
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Jun 2028, 29 months after the start.
Of 1,099 non-industry interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 29 months is above that.
Counting every sponsor, half of 1,187 studies reached it within 22 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →